Trevi Therapeutics Unveils Exciting Developments for Haduvio Ahead of Major Healthcare Conference Trevi Therapeutics is gearing up for the LifeSci Partners Corporate Access Event, making significant strides in treating chronic cough with their therapy Haduvio.

Trevi Therapeutics Unveils Exciting Developments for Haduvio Ahead of Major Healthcare Conference #USA #San_Francisco #Trevi_Therapeutics #Haduvio #chronic_cough

Trevi Therapeutics Expands Leadership with David Hastings as CFO to Drive Growth Trevi Therapeutics appoints David Hastings as Chief Financial Officer, aimed at advancing Haduvio™ and driving company growth.

Trevi Therapeutics Expands Leadership with David Hastings as CFO to Drive Growth #USA #New_Haven #Trevi_Therapeutics #Haduvio #David_Hastings

Trevi Therapeutics Reports Incisive Financial Results and Key Business Developments for Q3 2025 Trevi Therapeutics has announced its financial results for Q3 2025, unveiling plans for a comprehensive Phase 3 program aimed at addressing chronic cough in IPF patients.

Trevi Therapeutics Reports Incisive Financial Results and Key Business Developments for Q3 2025 #United_States #New_Haven #Trevi_Therapeutics #Haduvio #Phase_3_Trials

Trevi Therapeutics to Showcase Innovations at Stifel 2025 Healthcare Conference in New York Trevi Therapeutics will participate in the Stifel 2025 Healthcare Conference, presenting Haduvio, a potential treatment for chronic coughs.

Trevi Therapeutics to Showcase Innovations at Stifel 2025 Healthcare Conference in New York #USA #New_York #Healthcare_Conference #Trevi_Therapeutics #Haduvio

Trevi Therapeutics to Showcase RIVER Trial Data at 2025 ERS Congress Trevi Therapeutics announced two poster presentations highlighting Phase 2a RIVER trial data for Haduvio™ at the upcoming European Respiratory Society Congress 2025.

Trevi Therapeutics to Showcase RIVER Trial Data at 2025 ERS Congress #United_States #New_Haven #Trevi_Therapeutics #Haduvio #RIVER_trial

Trevi Therapeutics Executive Team to Attend Key Conferences This September Trevi Therapeutics, a clinical-stage biopharmaceutical company, announces participation in major healthcare conferences this September to discuss Haduvio™.

Trevi Therapeutics Executive Team to Attend Key Conferences This September #USA #New_Haven #Trevi_Therapeutics #Haduvio #chronic_cough

Trevi Therapeutics Announces Positive Financial Results and Progress in Haduvio Development In its latest conference, Trevi Therapeutics revealed promising results from its ongoing trials and solid financials that support the development of Haduvio.

Trevi Therapeutics Announces Positive Financial Results and Progress in Haduvio Development #United_States #New_Haven #Trevi_Therapeutics #Haduvio #IPF

Trevi Therapeutics Set to Feature at Key August Biotech Conferences Trevi Therapeutics will present its investigational therapy, Haduvio, at upcoming biotech conferences in August, highlighting its potential for chronic cough treatment.

Trevi Therapeutics Set to Feature at Key August Biotech Conferences #USA #Trevi_Therapeutics #Haduvio #chronic_cough #New_Haven,_Connecticut

Trevi Therapeutics to Present at the Leerink Partners Therapeutics Forum in Boston Trevi Therapeutics will showcase its investigational therapy, Haduvio™, at the Learink Partners Therapeutics Forum II in Boston, addressing chronic cough challenges.

Trevi Therapeutics to Present at the Leerink Partners Therapeutics Forum in Boston #United_States #Boston #Trevi_Therapeutics #Haduvio #chronic_cough

Trevi Therapeutics Completes $115 Million Offering to Fund Development of Chronic Cough Treatment Trevi Therapeutics has successfully closed a $115 million underwritten offering to support its chronic cough treatment initiatives, including Haduvio™.

Trevi Therapeutics Completes $115 Million Offering to Fund Development of Chronic Cough Treatment #United_States #New_Haven #Trevi_Therapeutics #Haduvio #Nasdaq_TRVI

Trevi Therapeutics Secures $100 Million from Underwritten Stock Offering Trevi Therapeutics has successfully announced a $100 million public offering of common stock to support its investigational therapy Haduvio™.

Trevi Therapeutics Secures $100 Million from Underwritten Stock Offering #United_States #New_Haven #Trevi_Therapeutics #Haduvio #Nasdaq_TRVI

Trevi Therapeutics Initiates Public Offering for Common Stock Funding Trevi Therapeutics has launched a public offering of its common stock valued at $100 million to support its investigational therapy Haduvio for chronic cough treatment.

Trevi Therapeutics Initiates Public Offering for Common Stock Funding #United_States #New_Haven #Trevi_Therapeutics #Haduvio #chronic_cough

Trevi Therapeutics to Showcase Breakthrough Chronic Cough Treatment at June Conferences Trevi Therapeutics will participate in significant June conferences to present findings on their novel chronic cough treatment, Haduvio™, targeting patients with IPF.

Trevi Therapeutics to Showcase Breakthrough Chronic Cough Treatment at June Conferences #USA #New_Haven #Trevi_Therapeutics #Haduvio #chronic_cough

#TRVI shares new insights from Phase 2a RIVER trial, highlighting Haduvio’s potential in treating refractory chronic cough. Promising results for patients with 10+ coughs/hour!
#TreviThera #ChronicCough #Biotech #Haduvio prismmarketview.com/trevi-therap...

Trevi Therapeutics Reveals Promising Findings from Phase 2a RIVER Trial of Haduvio for Chronic Cough Trevi Therapeutics presented new analyses from its Phase 2a RIVER trial for Haduvio, showing promising results in patients with refractory chronic cough at the ATS 2025 Conference.

Trevi Therapeutics Reveals Promising Findings from Phase 2a RIVER Trial of Haduvio for Chronic Cough #United_States #New_Haven #Trevi_Therapeutics #Haduvio #chronic_cough

Trevi Therapeutics Reports Financial Performance and Updates on Haduvio Development in Q1 2025 Trevi Therapeutics announces its financial results for the first quarter of 2025 and updates on the progress of Haduvio, an innovative therapy for chronic cough.

Trevi Therapeutics Reports Financial Performance and Updates on Haduvio Development in Q1 2025 #United_States #New_Haven #Clinical_Trials #Trevi_Therapeutics #Haduvio

Trevi Therapeutics Reports Strong Financial Results with Promising Trials for Haduvio in 2024 Trevi Therapeutics has released robust financial results for 2024, highlighting positive data from trials of Haduvio, a key therapy for chronic cough conditions.

Trevi Therapeutics Reports Strong Financial Results with Promising Trials for Haduvio in 2024 #USA #New_Haven #Trevi_Therapeutics #Haduvio #chronic_cough

Trevi Therapeutics Reports Encouraging Outcomes from Phase 2a RIVER Trial for Haduvio Treating Chronic Cough Conditions Trevi Therapeutics announces notable results from the Phase 2a RIVER Trial for Haduvio, a therapy for refractory chronic cough, indicating a significant drop in cough frequency.

Trevi Therapeutics Reports Encouraging Outcomes from Phase 2a RIVER Trial for Haduvio Treating Chronic Cough Conditions #United_States #New_Haven #Trevi_Therapeutics #Haduvio #chronic_cough

Trevi Therapeutics to Showcase Haduvio at Upcoming March Investor Conferences Trevi Therapeutics prepares for key investor conferences in March to discuss the investigational therapy Haduvio for chronic cough treatment.

Trevi Therapeutics to Showcase Haduvio at Upcoming March Investor Conferences #United_States #New_Haven #Trevi_Therapeutics #Haduvio #chronic_cough

Trevi Therapeutics Completes Patient Enrollment for Haduvio Trial Targeting Chronic Cough in IPF Trevi Therapeutics has finished enrolling patients for its Phase 2b CORAL trial, investigating Haduvio for chronic cough in IPF patients. Results are due in mid-2025.

Trevi Therapeutics Completes Patient Enrollment for Haduvio Trial Targeting Chronic Cough in IPF #United_States #New_Haven #Trevi_Therapeutics #Haduvio #IPF

Trevi Therapeutics to Present at Key Investor Conferences in February 2025 Trevi Therapeutics is set to attend several investor conferences in February, showcasing its novel therapy Haduvio for treating chronic cough.

Trevi Therapeutics to Present at Key Investor Conferences in February 2025 #USA #New_Haven #Trevi_Therapeutics #Haduvio #chronic_cough

Trevi Therapeutics Shares Key Updates Before Major Healthcare Conference in San Francisco Trevi Therapeutics provides essential updates on clinical trials and expected results for their ongoing studies in chronic cough therapies ahead of a major event.

Trevi Therapeutics Shares Key Updates Before Major Healthcare Conference in San Francisco #United_States #San_Francisco #Trevi_Therapeutics #Haduvio #chronic_cough

Trevi Therapeutics Secures $50 Million Funding Through Stock Offering Trevi Therapeutics has successfully priced a $50 million underwritten offering of its common shares to finance its clinical development programs.

Trevi Therapeutics Secures $50 Million Funding Through Stock Offering #United_States #New_Haven #Trevi_Therapeutics #Haduvio #chronic_cough

Trevi Therapeutics Confirms Phase 2b Trial Sample Size for Chronic Cough Treatment in IPF Patients Trevi Therapeutics announces that the sample size for its Phase 2b CORAL trial remains unchanged after a positive re-estimation result. Enrollment is at 75%.

Trevi Therapeutics Confirms Phase 2b Trial Sample Size for Chronic Cough Treatment in IPF Patients #United_States #New_Haven #Trevi_Therapeutics #Haduvio #IPF_Chronic_Cough

Trevi Therapeutics Shares Promising Findings from Nalbuphine Abuse Liability Study Trevi Therapeutics has unveiled positive results from its recent Human Abuse Potential study on nalbuphine, highlighting its lower 'Drug Liking' compared to traditional opioids.

Trevi Therapeutics Shares Promising Findings from Nalbuphine Abuse Liability Study #United_States #New_Haven #Trevi_Therapeutics #Nalbuphine #Haduvio